Genetic variation of the IL-28B promoter affecting gene expression.
about
Regulation of hepatic innate immunity by hepatitis C virusGenetic variants at the IFNL3 locus and their association with hepatitis C virus infections reveal novel insights into host-virus interactionsEx vivo induction of IFN-λ3 by a TLR7 agonist determines response to Peg-IFN/ribavirin therapy in chronic hepatitis C patients.Polymorphisms of T helper cell cytokine-associated genes and survival of hemodialysis patients - a prospective study.Zinc is a potent and specific inhibitor of IFN-λ3 signalling.Selection on a variant associated with improved viral clearance drives local, adaptive pseudogenization of interferon lambda 4 (IFNL4)Interferon lambda: opportunities, risks, and uncertainties in the fight against HCV.Pretreatment prediction of the outcome of response-guided peginterferon-α and ribavirin therapy for chronic hepatitis C.A single nucleotide polymorphism associated with hepatitis C virus infections located in the distal region of the IL28B promoter influences NF-κB-mediated gene transcriptionHost Genetic Factors and Dendritic Cell Responses Associated with the Outcome of Interferon/Ribavirin Treatment in HIV-1/HCV Co-Infected Individuals.Favourable IFNL3 genotypes are associated with spontaneous clearance and are differentially distributed in Aboriginals in Canadian HIV-hepatitis C co-infected individuals.Prevalence of Thymine--Adenine Dinucleotide Repeat, IL28B and IFNL4 in Thai Population and Correlation with Spontaneous Clearance and Treatment Outcome of Hepatitis C Infection.Is the use of IL28B genotype justified in the era of interferon-free treatments for hepatitis C?A thymine-adenine dinucleotide repeat polymorphism near IL28B is associated with spontaneous clearance of hepatitis C virus.Pharmacogenomics of hepatitis C infections: personalizing therapy.Responder Interferon λ Genotypes Are Associated With Higher Risk of Liver Fibrosis in HIV-Hepatitis C Virus CoinfectionHost factors determining the efficacy of hepatitis C treatment.Polymorphism Near the Interleukin-28B Gene and Anti-Hepatitis C Viral Response.Gene-disease association with human IFNL locus polymorphisms extends beyond hepatitis C virus infections.Tandem repeat sequence variation as causative cis-eQTLs for protein-coding gene expression variation: the case of CSTB.IFNL4 ss469415590 Variant Is Associated with Treatment Response in Japanese HCV Genotype 1 Infected Individuals Treated with IFN-Including Regimens.Association of serum IFN-λ3 with inflammatory and fibrosis markers in patients with chronic hepatitis C virus infection.Interleukin-28 gene polymorphisms may contribute to HBsAg persistence and the development of HBeAg-negative chronic hepatitis B.Immunomodulatory Function of Interleukin 28B during primary infection with cytomegalovirus.Meta-analysis: IL28B polymorphisms predict sustained viral response in HCV patients treated with pegylated interferon-α and ribavirin.Insulin resistance predicts sustained virological response to treatment of chronic hepatitis C independently of the IL28b rs12979860 polymorphism.Hepatic interferon-gamma-induced protein-10 expression is more strongly associated with liver fibrosis than interleukin-28B single nucleotide polymorphisms in hepatocellular carcinoma resected patients with chronic hepatitis C.
P2860
Q26824743-3C03FF29-EEF4-4B42-AD58-9301637E81D3Q27014831-E20260B8-64EE-402A-900F-FE186A8AF88CQ30444198-DEDC2C06-C90E-43FF-960E-C6E9141A549BQ33706698-4E14C87A-87FF-4951-B183-DCCF41A76EF0Q33720876-5252D156-6EB7-4278-B5BA-32B33B03FB6AQ34350873-DF8CC9D3-F89C-414A-BD3B-ABE831A5E520Q34433087-DA7E5753-16F9-4A93-B299-E799E705E35BQ34679526-4E33761C-E127-48A7-8E70-131C924DFB6FQ35014462-75DCB3D7-0050-4FB0-AF89-FE0E50BAC84FQ35095654-CC4BCF5D-8348-493D-9112-B895857C2248Q35381792-951C6971-2144-43D8-941B-DFDAEA5E88A9Q35566443-521B9D71-657D-47C5-9AFA-A63BFCDBC111Q35947900-F6AAB347-4AF0-41EB-A208-0944C19D89BDQ36295852-00277DA7-9214-4D25-AFB2-535EFBE8ECBAQ36632938-34350845-D5A8-4027-8F17-CA35E31D40EAQ37003049-31658A38-DCB6-4C0D-966C-07880F888AF7Q38056077-281FA72C-2FA9-479A-A834-FB141C1BA8E9Q38584278-6C4602CF-4F2B-4A18-B756-550A5E7E3BAEQ38859455-1288E4A6-14ED-42BF-96A0-36DCD911E2E1Q39351119-279AC70D-2358-41A3-B666-FB689B716B7BQ41576433-3A1D81B5-1324-45EA-8A70-CA2F8FD9BAE1Q41602462-7C9A60C8-4979-4509-83C3-85DCCF2113D4Q42217926-4D6FB8B2-3ACE-4E04-9EFF-92B1F11FB8F6Q42232134-B1C93BF4-AFE6-4F25-B432-C6E618C2157CQ42980402-7DA75F51-87C9-4264-93A2-8846A7F83885Q43826848-22857083-A88A-474E-B9E4-EA6635C6C099Q45047464-8C6A928D-DF0D-4468-A661-B58BAA9319F8
P2860
Genetic variation of the IL-28B promoter affecting gene expression.
description
2011 nî lūn-bûn
@nan
2011 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Genetic variation of the IL-28B promoter affecting gene expression.
@ast
Genetic variation of the IL-28B promoter affecting gene expression.
@en
Genetic variation of the IL-28B promoter affecting gene expression.
@nl
type
label
Genetic variation of the IL-28B promoter affecting gene expression.
@ast
Genetic variation of the IL-28B promoter affecting gene expression.
@en
Genetic variation of the IL-28B promoter affecting gene expression.
@nl
prefLabel
Genetic variation of the IL-28B promoter affecting gene expression.
@ast
Genetic variation of the IL-28B promoter affecting gene expression.
@en
Genetic variation of the IL-28B promoter affecting gene expression.
@nl
P2093
P2860
P1433
P1476
Genetic variation of the IL-28B promoter affecting gene expression.
@en
P2093
Makoto Nakanishi
Masashi Mizokami
Masaya Sugiyama
Takaji Wakita
Yasuhito Tanaka
P2860
P304
P356
10.1371/JOURNAL.PONE.0026620
P407
P577
2011-10-25T00:00:00Z